Amylin: The Other Hormone the Beta Cell Releases With Insulin

Every time your beta cells release insulin after a meal, they release a second hormone in the same package: amylin. Insulin gets the attention because it moves glucose out of the blood and into cells, but amylin does something complementary and just as clever. It controls how fast glucose arrives in the first place, quiets a competing sugar-raising signal, and tells your brain you have had enough to eat. Understanding amylin fills in a part of the glucose-control story that most people never hear about.

Two hormones, one release

Amylin, also called islet amyloid polypeptide, is a small peptide made in the same beta cells that make insulin. The two are stored together in the same secretory granules and released together into the bloodstream when blood glucose rises. In a healthy person, they travel out of the pancreas in a roughly fixed ratio, insulin in the larger amount and amylin in the smaller.

This co-packaging matters. It means the body has a built-in way to coordinate two different jobs with a single trigger. Insulin works mostly downstream, telling the liver, muscle, and fat what to do with glucose that is already circulating. Amylin works mostly upstream, shaping how much glucose shows up and how quickly. Think of insulin as the crew unloading a delivery truck and amylin as the dispatcher deciding how fast the trucks are allowed to pull up to the dock. Both are needed for a smooth operation.

Because amylin comes from the same cells as insulin, conditions that damage or exhaust those cells tend to lower both hormones together. In type 1 diabetes, where the beta cells are largely lost, amylin is deficient right alongside insulin. In type 2 diabetes, beta cell function declines over time, and the amylin response weakens with it. So the hormone is not a curiosity off to the side. It is part of the same machinery that fails when glucose control fails.

What amylin actually does after a meal

Amylin has three main effects, and each one addresses a different way that blood sugar can spike after eating.

It slows the stomach

The first effect is on gastric emptying, meaning the rate at which food leaves the stomach and enters the small intestine where sugars are absorbed. Amylin slows this exit. When the stomach empties more gradually, glucose trickles into the bloodstream rather than flooding in. That single change flattens the sharp rise in blood sugar that would otherwise follow a carbohydrate-heavy meal. It is a timing tool. The total amount of glucose absorbed does not change much, but the speed does, and speed is what drives the postprandial peak.

It suppresses glucagon

The second effect involves glucagon, a hormone from the alpha cells of the pancreas that raises blood sugar by prompting the liver to release stored glucose. After a meal, you want glucagon to stay low, since you are taking in sugar and do not need the liver adding more. Amylin helps hold glucagon down during this window. In diabetes, glucagon is often inappropriately high after eating, which pushes glucose up from a second direction. Amylin normally counteracts that. When amylin is deficient, this brake is weakened, and the liver contributes to the post-meal rise it should be sitting out.

It signals fullness

The third effect is on appetite. Amylin acts on regions of the brainstem that register satiety, the sense of having eaten enough. It reduces meal size and helps end eating. This is a slower, behavioral lever compared with the first two, but over days and weeks it influences how much a person eats and, in turn, body weight and glucose load. The satiety signal is one reason amylin has drawn interest well beyond the pancreas.

Put the three together and a pattern emerges. Insulin handles the glucose already in the blood. Amylin manages the inflow: it slows delivery from the gut, blocks an unwanted top-up from the liver, and reduces how much you eat next time. The two hormones are partners covering different phases of the same problem.

Why amylin is the lesser-known partner

If amylin is so useful, why does almost no one hear about it? Part of the answer is history. Insulin was isolated in the 1920s and transformed medicine within a decade. Amylin was not identified until the 1980s, discovered as the main component of the amyloid deposits found in the pancreatic islets of people with type 2 diabetes. It arrived on the scene decades later and had to be understood from a standing start.

Another part is chemistry. Human amylin is a sticky molecule that clumps together, which is exactly why it forms those islet deposits. That stickiness made it hard to study and hard to turn into a stable medicine. Researchers eventually engineered a modified, non-clumping version of the peptide so its effects could be delivered reliably. That work opened the door to using amylin biology in treatment, and it is an active area today, including combinations that pair amylin-like action with other gut hormone signals. I write about the science here rather than to recommend any specific product.

There is also a conceptual reason. The glucose story has long been told as an insulin story, and that framing is hard to shift. But blood sugar after a meal is the result of several signals arriving in sequence, not one. Amylin, the incretin hormones from the gut, glucagon, and insulin all overlap in those few hours. Leaving amylin out gives a tidier but less accurate picture.

None of this means amylin outranks insulin. Insulin remains the hormone you cannot live without. Amylin is the fine adjustment that makes the whole system behave smoothly, and appreciating it changes how you read the rise and fall of blood sugar around a meal.

This article is educational and not medical advice. If you have questions about your own blood sugar, medications, or diabetes care, please talk with your own clinician, who knows your history.